Development of Optimum Information System for Health Management in Patients with Crohn s Disease
|
|
- Dale Johns
- 5 years ago
- Views:
Transcription
1 , pp Development of Optimum Information System for Health Management in Patients with Crohn s Disease Seong-Ran Lee ¹Department of Medical Information, Kongju National University, 56 Gongjudaehak-ro, Kongju, Chungnam, , South Korea, lsr2626@naver.com Abstract. This paper is to develop optimum information system for health management in patients with Crohn s disease. The subjects of this paper were 124 patients who had been visited a general hospital which located in Chungnam area. As a result of this study, significantly positive changes of behaviors such as taking vegetables, drinking green tea, and practicing the healthy lifestyles of exercising diminished the progression rate of Crohn s disease. There was a significantly significant difference in hypertension control after information intervention(t=1.38, p=.032). This paper found that the health promoting behaviors in patients with Crohn s disease were increased by % compared with previous status and the patients positively perceived on information system. Therefore, the information system for the prevention of Crohn s disease can be applied to any hospital which has health promotion center. Keywords: Development, Optimum information system model, Preventive effects, Crohn s disease 1 Introduction Crohn s disease is a form of inflammatory bowel disease[1],[2]. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset. Inflammatory bowel disease is often confused with irritable bowel syndrome. Crohn s disease shares much in common with ulcerative colitis, another form of inflammatory bowel disease, but Crohn s disease can affect the whole gastrointestinal tract while ulcerative colitis only attacks the large intestine, and while ulcerative colitis can be cured by performing a total colectomy, surgery for Crohn s disease involves removing the damaged parts of the intestine and reconnecting the healthy parts, which does not cure Crohn s as it can recur after surgery, mostly at the site of the intestinal anastomosis or in other areas. Crohn s disease has an incidence of 1 to 20 cases per 100,000 individuals per year, and a prevalence of 8 to 246 per 100,000 individuals. The disease is more prevalent in northern countries of the world, as well as in northern of individual countries or other regions[3],[4]. Crohn s disease is sometimes associated with autoimmune pancreatitis. Infiltration of immunoglobulin G4 (IgG4)- positive plasma cells is sometimes detected in the colonic mucosa in patients with Crohn s disease. Changes in the expression profiles of specific proteins leads to ISSN: ASTL Copyright 2014 SERSC
2 serious colon diseases, including colitis. Sulfasalazine for treating Crohn s disease has a clinical limitation due to its adverse effects[5],[6]. As internet technology rapidly improves, clinical services are increasingly computerized in most hospitals. In order to effectively support patient care and clinical researches, information technologies are widely utilized to integrate clinical databases and disseminate information. However, most hospital information systems in Korea are still independently implemented and not fully integrated due to lack of standardization and security measure. In order to meet increasing demand for better patient care and upgrading clinical research, there is a need for a development and sharing of integrated clinical information system with a common database including clinical data collected from various hospitals. This paper attempted a new approach to develop an information system. Therefore, the purpose of this study is to develop optimum information system for health management in patients with Crohn s disease. 2 Materials and Methods 2.1 Study Materials This program was developed through review of existing literature, assessment of patients information needs, available updates on information, web site analysis and solicitation of expert advice throughout the development process[fig. 1]. Study participants were patients who were diagnosed with Crohn s disease at least 6 months ago by general surgery departments of two general hospitals in Chungnam area. The data were collected by interview and self-administered questionnaire from December 16, 2013 through April 18, This program was totally consisted 124 persons, it has been divided into two parts. 2.2 Study Methods The Chi-square test was performed to compare the general characteristics between two groups. In addition, it was measured by percentage and number. The pairwise t- test was done to compare the before and after intervention effect of health practice rate of patients with Crohn s disease. Information system planning - A method of analyzing, defining and designing the information. - A method dealing with interconnected data, processes, strategies, aims and efficient systems Setting goals - To understand key issues and opportunities with current applications - To provide executives with direction and a decisionmaking framework for the prevention of ulcerative colitis Information system usability -To develop technology for treating patients with ulcerative colitis. - To provide information systems with a developmental model. Fig. 1. Optimum Information System Structure for the Prevention of Crohn s Disease Copyright 2014 SERSC 225
3 3 Results 3.1 Basic Information of Study Subjects Table 1 presents basic information of study subjects. Male with 46.8% of the experimental group showed more than male with 38.7% of the control group according to gender. Married respondents with 56.5% of the control group were lower than survey respondents with 67.7 of the experimental group in marital status. Table 1. Basic Information of Study Subjects 3.2 Comparison of Degree of Self-Care Behavior of Before and After Information Intervention Table 2 represents comparison of degree of self-care behavior in patients with Crohn s disease before and after information intervention. Comparing the mean scores in the stress status, respondents score(52.07±0.82) after intervention significantly decreased than respondents(76.25±1.49) before intervention(t=1.94, p=.026). 226 Copyright 2014 SERSC
4 Table 2(A) Comparison of Health Practice of Before and After Information Intervention Items Before After /intervention Mean±S.D Mean±S.D t P Body weight control 59.28± ± Cholesterol 64.75± ± Stress status 76.25± ± Other disease 68.51± ± Hypertension control 57.83± ± Exercise 32.95± ± Table 2(B) Comparison of Health Practice of Before and After Information Intervention Items Before After /intervention Mean±S.D Mean±S.D t P Body weight control 59.28± ± Cholesterol 64.75± ± Stress status 76.25± ± Other disease 68.51± ± Hypertension control 57.83± ± Exercise 32.95± ± Having vegetable 48.16± ± Anxiety 62.59± ± Counseling 38.14± ± Smoking 49.72± ± Diabetes mellitus 61.48± ± Depression 72.39± ± Green tea drinking 47.91± ± Dandelion tea 15.76± ± drinking Chonggakkimchi ± ± intake Water drinking 41.60± ± Kiwi intake 29.14± ± Change of Health Behavior Practice Between Two Groups After Intervention Fig. 2 compares the change of health behavior practice between two groups The follow-up survey was estimated to be higher in the experimental group, regardless of the time elapsed of 40 days after the information intervention. However, the intervention effect was estimated to decrease more rapidly with time elapsed of 80 days after intervention in the experimental group as compared to the control group. Copyright 2014 SERSC 227
5 Fig. 2. Change of Health Behavior Practice Between Two Groups After Intervention 4 Discussion This paper is to develop of optimum information system model for preventive effects of Crohn s disease. The design and implementation of an information system brought better health related quality of life in patients with Crohn s disease than control group. As a result of this study, statistically significantly positive changes of behaviors such as taking vegetables and chongak kimchi, and drinking green tea diminished the progression rate of Crohn s disease. The findings were similar with the previous studies on the chronic disease[7],[8]. This study suggests that individuals with Crohn s disease should be targeted for specific health behavioral intervention to prevent the progression of Crohn s disease. Based on the results obtained by the study, it is anticipated that this paper may be used as basic data for developing and interventing health promotion behavior for the colorectal patients. However, the result shows that in order to maintain desirable food behaviors, it need periodic education programs related patients with Crohn s disease. Until the present, the limitation of patients with Crohn s disease lies in that there in nothing put into action despite the increase of knowledge. The result of this study would be the enhancement of practice behavior for the prevention of Crohn s disease. Thus, this paper indicated that the implemented systematic intervention showed significant positive effects on the life of subjects and health behavior. The quality of life in the experimental group has been enhanced as time passes by compared to control group, showed that it is an effective program for the prevention of Crohn s disease. Therefore, the management program for patients with Crohn s disease implemented by intervention research is quite meaningful in that it is evidence-based program development which will contribute in replicating the intention under field conditions for patients with Crohn s disease. 228 Copyright 2014 SERSC
6 The patients with Crohn s disease who had moderate exercise level and who were under diet care had better quality of life. Current practice of exercise in patients with Crohn s disease were obtained through intervention of information system. Therefore, adequate health practice behavior in patients with Crohn s disease will improve their quality of life in accordance with appropriate information system. The development about management system is so essential to the patients with Crohn s disease. For successful performance of this study, this paper had tried to provide various information to enhance the practice rate of health behavior in patients with Crohn s disease using a clinical management system. So, there were many changes which improve the quality of life in patients with Crohn s disease using the system. 5 Conclusion The purpose of this study is to find the effects of a new information system on prevention and management methods for patients with Crohn s disease. As a result of this study, positive changes of behaviors diminished the progression rate of osteoarthritis. This paper found that the health promoting behaviors in patients with Crohn s disease was increased by % compared with the previous status and the patients positively perceived on a clinical management system. Moreover, this paper showed that using the system as health practice tool was a good way to enhance the practice rate of health behavior in patients with Crohn s disease. References 1. Statistics Korea, Annual Report on the Cause of Death Statistics, (2011). 2. Miltermaier C, Dajaco. C., Waldhoer, T, Oeffer lbauer-ernst, A., Michsler, W., Beier M. et al, Impact of Depressive Mood on Relapse in Patients with Inflammatory Bowel Disease : A Prospective 18-Month Follow-up Study, Psycholmomatic Medicine 66, , (2004) 3. Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG, Prolonged Duration of Response to Infliximab in Early But Not Late Pediatric Crohn s Disease, Aa J, Gastroenterol, 95, , (2000) 4. Hyams T, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J. et al, Induction and Main Tenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn s Disease in Children, Gastroenterology, 132, (2007). 5. Peyrin-Biroulet L, Deltenre P, De Suray N, Branche, J., Sandborn WT, Colombel JF., Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn s Disease : Meta- Analysis of Placebo-Controlled Trials. Clin Gastroenterol Hepatol, 6, (2008) 6. Ministry of Security and Public Administration, Information System Audit Standard Revision (2010) 7. National Information Society Agency, The Commentary on the Information System Audit Standards, v3 National Information Society Agency (2009) 8. Siegel CA, Marden SM, Persing SM, Persing SM, Larson RJ, Sands, BE, Risk of Lymphoma Associated with Combination, Anti-tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn s Disease : A Meta-analysis, Clin Gastroenterol, Hepatol, 7, Copyright 2014 SERSC 229
Optimum Information System to Promote the Ability of Accomplishing Daily Life in Patients with Dementia
, pp.22-26 http://dx.doi.org/10.14257/astl.2014.61.06 Optimum Information System to Promote the Ability of Accomplishing Daily Life in Patients with Dementia Seong-Ran Lee¹ ¹Department of Medical Information,
More informationA New Experimental Model for Measurement of A Clinical Management System for the Prevention of Osteoarthritis
, pp.401-408 http://dx.doi.org/10.14257/astl.2013.29.82 A New Experimental Model for Measurement of A Clinical Management System for the Prevention of Osteoarthritis Seong-Ran Lee¹ ¹Department of Medical
More informationEffects of an Educational Intervention for the Prevention of Dry Eye Syndrome in Adults
, pp.120-124 http://dx.doi.org/10.14257/astl.2015.103.26 Effects of an Educational Intervention for the Prevention of Dry Eye Syndrome in Adults Seong-Ran Lee Department of Medical Information, Kongju
More informationClinical Application of Predictive Models for Health Promotion of Patients Undergoing Thyroidectomy
, pp.54-58 http://dx.doi.org/10.14257/astl.2013 Clinical Application of Predictive Models for Health Promotion of Patients Undergoing Thyroidectomy Seong-Ran Lee¹ ¹Department of Medical Information, Kongju
More informationA Design of Efficient Medical Information System to Enhance Health Behaviors after Radical Prostatectomy
, pp.24-29 http://dx.doi.org/10.14257/astl.2014.63.06 A Design of Efficient Medical Information System to Enhance Health Behaviors after Radical Prostatectomy Seong-Ran Lee Department of Medical Information,
More informationThe Effect of an Integrated Information System Adoption for Performance Ability Improvement in Hypertensive Patients
, pp.335-34 http://dx.doi.org/10.1457/ijseia.014.8..33 The Effect of an Integrated Information System Adoption for Performance Ability Improvement in Hypertensive Patients Seong-Ran Lee 1 Department of
More informationBiological Therapy for Inflammatory Bowel Disease in Children
pissn: 2234-8646 eissn: 2234-8840 http://dx.doi.org/10.5223/kjpgn.2012.15.1.13 Pediatric Gastroenterology, Hepatology & Nutrition 2012 March 15(1):13-18 Review Article PGHN Biological Therapy for Inflammatory
More informationCancer Risk with IBD Therapies How to Discuss with your Patients?
Cancer Risk with IBD Therapies How to Discuss with your Patients? Douglas L Nguyen, MD Assistant Clinical Professor of Medicine University of California, Irvine Medical Center H.H. Chao Comprehensive Digestive
More informationEfficacy of Early Infliximab Treatment for Pediatric Crohn s Disease: A Three-year Follow-up
pissn: 223-866 eissn: 223-880 http://dx.doi.org/.223/pghn.2012.1..23 Pediatric Gastroenterology, Hepatology & Nutrition 2012 December 1():23-29 Original Article PGHN Efficacy of Early Infliximab Treatment
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationDevelopment of Computer-Aided Medication Education for Drug Abuse Prevention
Development of Computer-Aided Medication Education for Drug Abuse Prevention Seong-Ran Lee Department of Medical Information, Kongju National University, 182 Gongju daehak-ro, Kongju, Chungnam, 314-701,
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationPropriety of Internet Use Time for Internet Addiction among Korean Adolescents
Vol.128 (Healthcare and Nursing 26), pp.23-27 http://dx.doi.org/10.14257/astl.26. Propriety of Internet Use Time for Internet Addiction among Korean Adolescents Eun Sun So 1, Young-Ran Chin 2 1 Chonbuk
More informationSelby Inflamm Bowel Dis. 2008:14:
Medical Management of Inflammatory Bowel Disease Freddy Caldera D.O. Assistant Professor Division of Gastroenterology Objectives Discuss Crohn s disease and Ulcerative Colitis Discuss Medications for Inflammatory
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationIBD Tools to Aid in the Accurate Diagnosis of Inflammatory Bowel Disease
IBD Tools to Aid in the Accurate Diagnosis of Inflammatory Bowel Disease Inflammatory Bowel Disease Experts in Autoimmunity Inova Diagnostics offers a complete array of methods to aid in the diagnosis
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationULCERATIVE COLITIS. Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC
ULCERATIVE COLITIS Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC What is Ulcerative Colitis? Ulcerative colitis (UC) is a disease marked by inflammation
More informationHow do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
More informationCrohn's Disease. What causes Crohn s disease? What are the symptoms?
Crohn's Disease Crohn s disease is an ongoing disorder that causes inflammation of the digestive tract, also referred to as the gastrointestinal (GI) tract. Crohn s disease can affect any area of the GI
More informationHow Safe and Effective is Infliximab in the Treatment of Children with Moderate to Severe Crohn s disease?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 How Safe and Effective is Infliximab
More informationClinical Course of Infliximab Treatment in Korean Pediatric Ulcerative Colitis Patients: A Single Center Experience
pissn: 2234-8646 eissn: 2234-8840 http://dx.doi.org/10.5223/pghn.2014.17.1.31 Pediatric Gastroenterology, Hepatology & Nutrition 2014 March 17(1):31-36 Original Article PGHN Clinical Course of Infliximab
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationUse of extrapolation in small clinical trials:
Use of extrapolation in small clinical trials: Infliximab for pediatric ulcerative colitis Jessica J. Lee, MD, MMSc Medical Officer Division of Gastroenterology and Inborn Errors Products CDER/ FDA 1 Learning
More informationThe National Association of Crohn s and Colitis of Trinidad and Tobago CROHN S DISEASE AND ULCERATIVE COLITIS GENERAL PATIENT INFORMATION
The National Association of Crohn s and Colitis of Trinidad and Tobago CROHN S DISEASE AND ULCERATIVE COLITIS GENERAL PATIENT INFORMATION You are reading this pamphlet because you or someone you known
More informationPrevalence of Irritable Bowel Syndrome among Medical Students and Interns in Jeddah, Saudi Arabia
Prevalence of Irritable Bowel Syndrome among Medical Students and Interns in Jeddah, Saudi Arabia Mohammed Y Hasosah 1*, Samer A Alamri 2, Faisal A Al-Husayni 2, Rakan M. Aljedaani 2, Mohammad A Zwawy
More informationDr David Epstein Vincent Pallotti Hospital and University of Cape Town
Inflammatory Bowel Disease Management in South Africa in 2016 Pharmaceutical Care Management Association Dr David Epstein Vincent Pallotti Hospital and University of Cape Town Inflammatory Bowel Disease
More information11/13/11. Biologics for CD and CUC: The Impact on Surgical Outcomes. Principles of Successful Intestinal Surgery
Biologics for CD and CUC: The Impact on Surgical Outcomes Robert R. Cima, M.D., M.A. Associate Professor of Surgery Division of Colon and Rectal Surgery Overview Antibody based medications (biologics)
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION VEDOLIZUMAB (Entyvio Takeda Canada Inc.) Indication: Crohn s Disease Recommendation: The CADTH Canadian Drug Expert Committee (CDEC) recommends
More informationUlcerative Colitis. ulcerative colitis usually only affects the colon.
Ulcerative Colitis Introduction Ulcerative colitis is an inflammatory bowel disease. It is one of the 2 most common inflammatory bowel diseases. The other one is Crohn s disease. Ulcerative colitis and
More informationEast west gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort
East west gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort diseasespictures.com Balazs Radnai and Martin Eigler Statistik II. Course 27.01.2014. Introduction
More informationRelated Media. Dr. Rubin discusses smoking as a trigger (00:00, MP3 xx MB)
Leading Expert Has Answers on Crohn s Disease David T. Rubin M.D., Assistant Professor of Medicine at the University of Chicago Pritzker School of Medicine and leading authority in Crohn s disease and
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Community Plan Medical Benefit Drug Policy Policy Number: CS2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationOf Treatment For Inflammatory Bowel Diseases
Balancing The Risks And Benefits Of Treatment For Inflammatory Bowel Diseases Corey A. Siegel, MD Assistant Professor of Medicine Dartmouth Medical School Director, Inflammatory Bowel Diseases Center Dartmouth-Hitchcock
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationDoncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 1.5 Chronic Bowel Disorders (including IBD) Aminosalicylates: Mesalazine 400mg and 800mg MR Tablets (Octasa) Mesalazine 1.2g MR Tablets (Mezavant XL) Mesalazine
More informationCrohn's disease CAUSES COURSE OF CROHN'S DISEASE TREATMENT. Sulfasalazine
Crohn's disease Crohn's disease is an inflammatory condition of the digestive tract that affects children and adults. Common features of Crohn's disease include mouth sores, diarrhea, abdominal pain, weight
More informationFirst Name. Profession. Weight lbs. Weight 1 year ago lbs. Min. Adult Weight lbs. at age Maximum Weight lbs. at age
Date Time Dietary consultation involves a health profile whose purpose is not to establish a diagnosis, but rather to determine a client's health status in order to guide his or her weight loss plan. A
More information1. Comparative effectiveness of vedolizumab
Cost-effectiveness of vedolizumab (Entyvio ) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were
More informationClinically proven to quickly relieve symptoms of common gastrointestinal disorders. TERRAGASTRO - Good health starts in the gut
Clinically proven to quickly relieve symptoms of common gastrointestinal disorders GASTROINTESTINAL DISEASE Referred to as gastrointestinal diseases, they are common disorders which affect the esophagus,
More informationEfficacy of Adalimumab in Korean Patients with Crohn s Disease
Gut and Liver, Vol. 10, No. 2, March 2016, pp. 255-261 ORiginal Article Efficacy of Adalimumab in Korean Patients with Crohn s Disease Il Woong Sohn, Sung Tae Kim, Bun Kim, Hyun Jung Lee, Soo Jung Park,
More informationCommunicating with the IBD Patient: How to convey risks and benefits
Communicating with the IBD Patient: How to convey risks and benefits October 30, 2011 ACG Postgraduate Course National Harbor, Maryland Corey A. Siegel, MD Assistant Professor of Medicine Dartmouth Medical
More informationINFLAMMATORY BOWEL DISEASE. Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic
INFLAMMATORY BOWEL DISEASE Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic WHAT IS INFLAMMATORY BOWEL DISEASE (IBD)? Chronic inflammation of the intestinal tract Two related
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationTestimony Submitted by: Eric Zuckerman, DO Bloomfield Hill, MI Board Chairman, Pediatric IBD Foundation
Testimony Submitted by: Carlo Di Lorenzo, MD Nationwide Children s Hospital, Columbus, OH President, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Benjamin Gold, MD, Children's
More informationControversies in IBD: Resolving clinical dilemmas using Cochrane reviews
Controversies in IBD: Resolving clinical dilemmas using Cochrane reviews DR. NILESH CHANDE COORDINATING EDITOR, IBD REVIEW GROUP; UNIVERSITY OF WESTERN ONTARIO, LONDON, ON CANADA An international organisation
More informationEvolve180 / Ideal Northwest Health Profile
Evolve180 / Ideal Northwest Health Profile ABOUT YOU First Name: Last Name: Address: City: State: Zip: Phone: Email: Date of Birth: Age: Height: Occupation: How did you find out about our program? Marital
More informationProf. Dr. Mufti Munsurar Rahman Dept. of Medicine Enam Medical College Hospital
Prof. Dr. Mufti Munsurar Rahman Dept. of Medicine Enam Medical College Hospital Functional constipation : prevalence and life style factors in a district of Bangladesh Perveen I, Rahman MM, Saha M, Parvin
More informationTreatment of Pediatric IBD: What is Different?
Treatment of Pediatric IBD: What is Different? January 13, 2017 Michael Kappelman MD, MPH University of North Carolina at Chapel Hill Overview Is Pediatric IBD the same disease? Treatment considerations
More informationWeight: lbs. Weight 1 year ago: lbs. Min. Adult Weight: lbs at age
Health Profile ALTH PROFILE Dietary consultation involves a health profile whose purpose is not to establish a diagnosis, but rather to determine a client s health status in order to guide his or her weight-loss
More informationLower Gastrointestinal Tract KNH 406
Lower Gastrointestinal Tract KNH 406 Lower GI Tract A&P Small Intestine Anatomy Duodenum, jejunum, ileum Maximum surface area for digestion and absorption Specialized enterocytes from stem cells of crypts
More informationType 2 Diabetes. What is diabetes? What is type 2 diabetes? What is type 1 diabetes? Understanding blood glucose and insulin
Page 1 of 7 Type 2 Diabetes Type 2 diabetes occurs mainly in people aged over 40. The first-line treatment is diet, weight control and physical activity. If the blood sugar (glucose) level remains high
More informationDigestion: Small and Large Intestines Pathology
Digestion: Small and Large Intestines Pathology Dr. Ritamarie Loscalzo Medical Disclaimer: The information in this presentation is not intended to replace a one onone relationship with a qualified health
More informationPatient Name Date of Birth Age. Other phone ( ) . Other
GASTROINTESTINAL & MINIMALLY INVASIVE SURGERY HEALTH HISTORY QUESTIONNAIRE Date Patient Name _ Date of Birth Age Daytime phone ( ) Other phone ( ) Email How did you hear about us? My doctor Yellow pages
More informationDiarrhea may be: Acute (short-term, usually lasting several days), which is usually related to bacterial or viral infections.
Pediatric Gastroenterology Conditions Evaluated and Treated Having a child suffer with abdominal pain, chronic eating problems, or other gastrointestinal disorders can be a very trying time for a parent.
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationModesto Gastroenterology Medical Corporation
Page 1 of 5 Modesto Gastroenterology Medical Corporation Magdy S. Elsakr, M.D. Board Certified Gastroenterologist 2336 Sylvan Avenue, Suite A, Modesto, CA 95355, Phone: 209-338-0292, Fax: 209-338-0298
More informationCase Report Cytomegalovirus Colitis with Common Variable Immunodeficiency and Crohn s Disease
Volume 2015, Article ID 348204, 4 pages http://dx.doi.org/10.1155/2015/348204 Case Report Cytomegalovirus Colitis with Common Variable Immunodeficiency and Crohn s Disease Betül Ünal, Cumhur Ebrahim BaGsorgun,
More informationFactsheet - Risk factors for inflammatory bowel disease (IBD)
Key Points Knowledge of the causes or risk factors for Crohn s disease and ulcerative colitis is limited. Many genes have been shown to be associated with the development of IBD. Research is continuing
More informationPEDIATRIC INFLAMMATORY BOWEL DISEASE
PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric Gastroenterology Advocate Children s Hospital Disclosers Abbott Nutrition - Speaker Inflammatory Bowel Disease Chronic inflammatory disease
More informationOnce Daily Dosing for Induction and Maintenance of Remission in Ulcerative Colitis
Once Daily Dosing for Induction and Maintenance of Remission in Ulcerative Colitis John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University JKM 2014 Svartz N. Acta Med Scand
More informationTechnology appraisal guidance Published: 26 August 2015 nice.org.uk/guidance/ta352
Vedolizumab for treating moderately to severely erely active Crohn's disease after prior therapy Technology appraisal guidance Published: 26 August 2015 nice.org.uk/guidance/ta352 NICE 2017. All rights
More informationAdalimumab Treatment in Pediatric-Onset Crohn s Disease Patients after Infliximab Failure: A Single Center Study
pissn: 2234-8646 eissn: 2234-8840 http://dx.doi.org/10.5223/pghn.2016.19.2.116 Pediatr Gastroenterol Hepatol Nutr 2016 June 19(2):116-122 Original Article PGHN Adalimumab Treatment in Pediatric-Onset Crohn
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationIBD in teenagers Biological and Transition
IBD in teenagers Biological and Transition Dr Warren Hyer Consultant Paediatric Gastroenterologist St Mark s Hospital Chelsea and Westminster Hospital Conflict of Interest None to declare Fee for presentation
More informationLooking for Answers. IBD Research March 9, Dr. Benjamin Click, MD MS Associate Staff Cleveland Clinic
Looking for Answers IBD Research 2019 March 9, 2019 Dr. Benjamin Click, MD MS Associate Staff Cleveland Clinic Disclosures No relevant financial disclosures There is still no cure for IBD Why me? ETIOLOGY
More informationClinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab
Clinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab Clinical Policy Number: 01.01.03 Effective Date: January 1, 2016 Initial Review Date: September 16, 2015 Most Recent
More informationSpeaker Introduction
Speaker Introduction Stephen B. Hanauer, MD Professor of Medicine and Clinical Pharmacology University of Chicago Pritzker School of Medicine Chief of Gastroenterology, Hepatology, and Nutrition University
More informationCertain genes passed on from parent to child increase the risk of developing Crohn's disease, if the right trigger occurs.
Topic Page: Crohn's disease Definition: Crohn's disease from Benders' Dictionary of Nutrition and Food Technology Chronic inflammatory disease of the bowel, commonly the terminal ileum, of unknown aetiology,
More informationvedolizumab (Entyvio )
vedolizumab (Entyvio ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ),
More informationClinical Study Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis
Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2013, Article ID 192794, 6 pages http://dx.doi.org/10.1155/2013/192794 Clinical Study Clinical Study of the Relation between
More informationUpdate in Pediatric IBD: 2018
Update in Pediatric IBD: 2018 Jeffrey S. Hyams, MD Head, Division of Digestive Diseases, Hepatology and Nutrition Mandell-Braunstein Family Endowed Chair in Pediatric Inflammatory Bowel Disease Connecticut
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationBiologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationThe Role of Surgery in Inflammatory Bowel Disease. Cory D Barrat, MD Colon and Rectal Surgeon Mercy Health
The Role of Surgery in Inflammatory Bowel Disease Cory D Barrat, MD Colon and Rectal Surgeon Mercy Health THANKS FOR INVITING ME! I have no financial disclosures Outline - Who am I and what do I do? -
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 October 2010 MEZAVANT LP 1200 mg, prolonged-release gastro-resistant tablets B/60 (CIP code: 378 689-2) Applicant
More informationWeight: lbs. Weight 1 year ago: lbs. Min. Adult Weight: lbs at age
Health Profile ALTH PROFILE Dietary consultation involves a health profile which purpose is not to establish a diagnosis, but rather to determine a client s health status in order to guide his or her weight-loss
More informationCLINICAL INSIGHTS 01
P2 Borrowing a Treatment Paradigm From Rheumatoid Arthritis P4 Antidrug Antibody Monitoring in Practice P6 Proactive Drug Monitoring Informs Therapeutic Dose Adjustments P7 Keeping Patients in Remission
More informationColon, or Colorectal, Cancer Information
Colon, or Colorectal, Cancer Information Definition Colon, or colorectal, cancer is cancer that starts in the large intestine (colon) or the rectum (end of the colon). Other types of cancer can affect
More informationMalignancy Risk in Pediatric IBD: What to tell parents and patients?
Malignancy Risk in Pediatric IBD: What to tell parents and patients? Corey A. Siegel, MD, MS Geisel School of Medicine at Dartmouth Dartmouth-Hitchcock Medical Center Digestive Disease Week 2017 Chicago,
More informationRisk = probability x consequence
Explaining Risks of IBD Therapy to Parents and Patients December 4, 2009 CCFA Advances in IBD Hollywood, FL Corey A. Siegel Assistant Professor of Medicine, Dartmouth Medical School Director, Dartmouth-Hitchcock
More informationLevel 2. Non Responsive Celiac Disease KEY POINTS:
Level 2 Non Responsive Celiac Disease KEY POINTS: Celiac Disease (CD) is an autoimmune condition triggered by ingestion of gluten leading to intestinal damage and a variety of clinical manifestations.
More informationEtiology, Assessment and Treatment
Etiology, Assessment and Treatment Andrew Tinsley MD, MS Associate Director of IBD Center Assistant Professor of Medicine Penn State College of Medicine Abbvie Janssen Nestle 1 To review the prevalence
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationFatal Gastrointestinal Perforations in sudden death cases in Last 10 years at UMMC- Malaysia
Fatal Gastrointestinal Perforations in sudden death cases in Last 10 years at UMMC- Malaysia Dr. OP Murty, Dr. Lye Yik Fan, Dr. Tan Ley Siang, Dr. Nurull Eddayu binti Hasbullah, Dr. Nurul Azwa binti Mohd
More informationBiomarkers of GI tract diseases. By Dr. Gouse Mohiddin Shaik
By Dr. Gouse Mohiddin Shaik Introduction The gastrointestinal (GI) tract is a complex system performing multiple biological functions which are anatomically distributed Site for food processing and absorption
More informationFecal incontinence causes 196 epidemiology 8 treatment 196
Subject Index Achalasia course 93 differential diagnosis 93 esophageal dysphagia 92 95 etiology 92, 93 treatment 93 95 work-up 93 Aminosalicylates, pharmacokinetics and aging effects 36 Antibiotics diarrhea
More informationLast Name: First Name: Address: Apt/Unit #: City: State: Zip: Best Contact Phone Number: Date of Birth: Age: Profession:
Health Profile Our 30/10 program is intended to help participants with their personal weight loss efforts. We are not a medical facility, and our staff cannot give you medical or psychological advice.
More informationPatient Registration Please fill out and bring to your first visit. (Please Print) PATIENT INFORMATION. P.O. Box: City: State: ZIP Code:
Nutrition Works LLC 805 Stevens Avenue Portland, Maine 04103 (207) 772-6279 Fax (207) 347-4281 Susan Quimby, R.D., L.D. Judy Donnelly, R.D., L.D. Kim Norbert, M.S., R.D., L.D. Patsy Catsos, M.S., R.D.,
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 285.8 T2 Effective Date: November 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationWhat is ulcerative colitis?
What is ulcerative colitis? Ulcerative colitis is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. Ulcers form where inflammation has killed the cells
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationWhat is Inflammatory Bowel Disease (IBD)?
INFLAMMATORY BOWEL DISEASE (IBD) What is Inflammatory Bowel Disease (IBD)? Inflammatory bowel disease, or IBD, is when there is inflammation, or swelling, in the gastrointestinal (GI) tract and a lifelong
More information